Clin2
NCT07414290Possibly a fitNot yet recruiting

Gene therapy trial for Parkinson's with GBA1 mutation

Parkinson Disease (PD)

Part of Brain & nervous system clinical trials.

This trial tests a gene therapy product called VGN-R08b for people with Parkinson's disease who have a specific genetic change (GBA1 mutation). The goal is to help improve movement and daily function.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
17 people
Ages
30 years to 70 years
Study type
Interventional

Who can take part

  • You are 30 to 70 years old.
  • You have Parkinson's disease caused by a specific change in the GBA1 gene.
  • Your GBA enzyme activity is lower than normal.
  • You are able to walk without a wheelchair, though you may use a walker or cane.
  • Your Parkinson's symptoms are not fully controlled by your current medications, with at least 2.5 hours of 'off' time each day.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07100171Recruiting· Early Phase 1
GM101 injection for advanced Parkinson's disease

This trial tests an investigational gene therapy injection called GM101 for people with advanced Parkinson's disease whose symptoms are not well controlled by standard medications. The study will see if this treatment can help improve movement and quality of life.

Changsha
NCT07685444Not yet recruiting· Early Phase 1
Gene therapy for Parkinson's with GBA1 mutation

This study tests a new gene therapy called LY-N001, which is injected directly into the brain. It is for people with moderate to advanced Parkinson's disease who have a specific genetic change in the GBA1 gene. The goal is to see if this treatment is safe and can help improve symptoms.

Hefei, Anhui
NCT04101968Recruiting
Study of GBA changes in Parkinson’s using multiple tests

This study looks at people with Parkinson’s who carry a specific genetic change in the GBA gene. It uses several tests (including brain scans) to understand the disease better and may help guide future treatments.

Portland, Oregon
NCT07215403Not yet recruiting· Phase 2
Gene therapy study for advanced Parkinson's disease

This trial tests a gene therapy for people with advanced Parkinson's disease (at least 10 years since diagnosis). It uses a special infusion to deliver treatment directly into the brain. The goal is to see if it can improve motor symptoms.

Cleveland, Ohio
NCT06732180Recruiting· Phase 1
Testing a new drug (GT-02287) for Parkinson's disease

This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.

Darlinghurst, New South Wales
NCT06451419Enrolling by invitation
Non-motor symptoms in GBA-related Parkinson's disease

This study looks at non-motor symptoms (like mood, thinking, or sleep problems) in people with a specific genetic change linked to Parkinson's disease. It compares those with the GBA gene change to those without it to see how symptoms differ.

Pozuelo de Alarcón, Madrid

Hear when a new Parkinson Disease (PD) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.